


# Characterization of RIT1 signaling by proteome, phosphoproteome, and transcriptome profiling

## Background

Ras-like-in-all-tissues (*RIT1*) is a small GTPase of the Ras family that shares 50% homology with KRAS.

*RIT1* is mutated in 2% of lung adenocarcinomas and amplified in a further 7-14%<sup>1</sup>.


However, while *RIT1*'s role in some Ras-related pathways has been investigated, **there has been no unbiased mapping of downstream *RIT1* regulation and signaling pathways in human cells.**



## Questions


- Does *RIT1* regulate the same pathways and processes as KRAS?
- How does increased expression of wild-type *RIT1* affect signaling, compared to *RIT1* and KRAS oncogenic variants?

## Methods



## Results


### *RIT1*<sup>WT</sup> and *RIT1*<sup>M90I</sup> induce changes in the proteome and phosphoproteome similar to KRAS variants




Among the top proteins with increased abundance in KRAS variant and *RIT1* cells was FOSL1, a transcription factor known to be upregulated by RAS.

Similarly, TXNIP, a protein shown to be suppressed by HRASG12V, was among the top proteins with decreased abundance.


### *RIT1*<sup>WT</sup> and *RIT1*<sup>M90I</sup> also induce changes in the transcriptome similar to KRAS variants




## Proteome and transcriptome profiles are moderately correlated



## *RIT1* promotes an epithelial-to-mesenchymal transition



Quantification of Vimentin, Snail, and Slug mRNA by qRT-PCR indicate these EMT genes are indeed upregulated at the transcript level.



**In line with a functional EMT, *RIT1*-transformed cells show enhanced migration in a scratch assay, with *RIT1*<sup>WT</sup> and *RIT1*<sup>M90I</sup> closing the scratch wound up to 1.5x and 1.9x faster than vector control cells respectively.**

## Conclusions

- RIT1* and KRAS signaling networks exhibit overall similarity, suggesting that **oncogenic *RIT1* can hijack and activate canonical Ras effector pathways.**
- Amplification of wild-type *RIT1* expression phenocopies oncogenic *RIT1* activation**
- Both *RIT1*<sup>WT</sup> overexpression and *RIT1*<sup>M90I</sup> promote an EMT phenotype**

## Acknowledgements

This work was supported in part by an NSF IGERT DGE-1258485 fellowship. RNA-sequencing was performed by the Fred Hutch Genomics Shared Resource. Microscopy and image analysis was performed with assistance from Fred Hutch Cellular Imaging Shared Resource.

## References

- TCGA, Nature, 2014.
- Keenan et al., NAR, 2019.

## Future Directions

- Investigate oncogenic properties of amplified wild-type *RIT1* in human tumors
- Further determine how *RIT1* regulates EMT and whether it does so *in vivo*
- Analyze RNA-seq and phosphoproteomic data further to determine how *RIT1* and KRAS affects alternative splicing processes

## Contact

Email: [aprillo@uw.edu](mailto:aprillo@uw.edu) or [alo2@fredhutch.org](mailto:alo2@fredhutch.org)  
Twitter: @pamyl  
GitHub: aprilflow  
Berger Lab (C2-201)